CombinatoRx to pocket $42M in new collaboration

CombinatoRx has signed a deal with Angiotech Pharmaceuticals worth $42 million at closing. Boston-based CombinatoRx will gain $27 million up front and a $15 million equity investment to join a collaboration to develop new drug-device combinations and local interventional medicines. CombinatoRx has been involved in searching for new combination drugs. The intellectual property created in the collaboration will be jointly owned.

- read this press release for more information

Suggested Articles

The back-to-back pivotal successes tee Incyte up to talk to regulators about bringing the JAK inhibitor to market.

The judge also ordered Reynolds to pay $280,000 in forfeiture and around $7.5 million in restitution as punishment for his crimes. 

NeoTX Therapeutics has nabbed a healthy $45 million third funding round as it looks to continue work on its early-stage cancer combo test.